Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16653188 | 1.00 | HPGD (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL29958800 | 1.00 | HPGD (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL16653189 | 1.00 | HPGD (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL16653187 | 1.00 | HPGD (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL14671956 | 0.86 | HPGD (0.48) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL2777507 | 0.86 | HPGD (0.48) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL14671811 | 0.86 | HPGD (0.48) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL15740632 | 0.83 | EPHX1 (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL31080572 | 0.83 | EPHX1 (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL31080158 | 0.83 | EPHX1 (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9642852-B2 | Sulfur-containing bicyclic compound | ASTELLAS PHARMA INC. (JP) | 2017-05-09 | — | — | US | disclosed |
| US-9642852-B2 | Sulfur-containing bicyclic compound | ASTELLAS PHARMA INC. (JP) | 2017-05-09 | — | — | US | disclosed |
| EP-3059239-A1 | SULFUR-CONTAINING BICYCLIC COMPOUND | Astellas Pharma Inc. (JP) | 2016-08-24 | — | — | EP | disclosed |
| US-20150231138-A1 | SULFUR-CONTAINING BICYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-08-20 | — | — | US | disclosed |
| US-9051339-B2 | Sulfur-containing bicyclic compound | ASTELLAS PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-9051339-B2 | Sulfur-containing bicyclic compound | ASTELLAS PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20150111876-A1 | SULFUR-CONTAINING BICYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111876-A1 | SULFUR-CONTAINING BICYCLIC COMPOUND | GABRB1, GABRA1, GABBR1 | HPGD 4596/4885RECQL 3304/4885EPHX1 4662/4885 |
| US-20150231138-A1 | SULFUR-CONTAINING BICYCLIC COMPOUND | GABBR1, GABRB1, GRIN2C | HPGD 4456/4885RECQL 4018/4885EPHX1 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.